An observational study in Sleep Disorder, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-09-05.
Sponsored by NYU Langone Health · Observational
The purpose of this study is to determine the sleep patterns of subjects with or without sleep disturbances (insomnia, sleep apnea) and compare these findings with their previous FDG/PIB PET, structural MRI and brain blood flow scams performed during their participation in the Following studies 'Alzheimer's Disease Core Center (ADCC) Clinical Evaluation' (IRB: 2942), MRI Progression Markers of Cognitive Decline in the Elderly' (IRB:09-0586), or 'Imaging Neuro inflammation in Alzheimer's Disease with [11C] Arachidonic Acid (AA) and PET'(IRB: 10-00442).
2,162 studies on the registry are indexed under Sleep Apnea Syndromes; 290 are open to participants now.
This study's enrollment of 28 is below the median of 109 across 654 observational studies indexed under Sleep Apnea Syndromes.
Browse Sleep Apnea Syndromes studies →NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.
Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
80 cognitively healthy subjects (normal or MCI) previously enrolled in Alzheimer's Disease Core Center (ADCC) and CBH studies who have agreed to be contacted about future research studies will be asked to additionally participate in this study. The age range of the subjects will be of 55-90 years based on the incidence of dementia in middle age and elder adults.
Exclusion Criteria:
Patients with clinical dementia rating of 0.5 or a global deterioration scale of 3.
Diagnostic Test: Structural 3T MRI · Diagnostic Test: MRI Based Perfusion Imaging · Diagnostic Test: VR-CO2 MRI Scans
Clinical Dementia Rating \[CDR\] of 0 or Global Deterioration Scale \[GDS\] of 1-2
Diagnostic Test: Structural 3T MRI · Diagnostic Test: MRI Based Perfusion Imaging · Diagnostic Test: VR-CO2 MRI Scans
measures of global and hippocampal atrophy)
brain blood flow
reduced vaso reactivity to carbon dioxide
Decreased cerebral blood flow (CBF)
Measured by perfusion MRI
Time frame: 1 Week
Measure of vasoreactivity to CO2 (VRCO2)
subjects will breath through a respiratory tube and CO2 will be meaured
Time frame: 1 Week
Increase in cortical AB plaque burden
Measured by PIB PET
Time frame: 1 Week
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NYU Langone Health